Aspirin dilemma: to stop or not to stop during brain bleed treatment?

NCT ID NCT07240454

Recruiting now Disease control Sponsor: Tao Liu Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with a chronic subdural hematoma (a slow brain bleed) who are already taking aspirin should continue or stop it while receiving non-surgical care. Researchers will follow 143 participants for 6 months to see if the hematoma comes back or worsens. The goal is to provide better guidance on managing aspirin use in this situation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin
What this could lead to: If it works, this could help doctors give clearer guidance on whether to keep taking aspirin during conservative treatment for chronic subdural hematoma, potentially reducing the risk of the hematoma coming back or getting worse.
What could go wrong: This is a relatively small trial (143 people) and is not a late-stage study, so results may not apply to everyone. The main risk is that continuing aspirin might increase bleeding, while stopping it could raise the chance of a heart attack or stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SUBDURAL HEMATOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SUBDURAL HEMATOMA

Contacts and locations

Locations

Tianjin Medical University General Hospital
RECRUITING

Tianjin, China
Xuanwu Hospital Capital Medical University
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.